Therapy for vitiligo
AssigneeClinuvel Pharmaceuticals Limited
InventorPhilippe Wolgen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
Claims14
Method for treating or preventing vitiligo in a subject comprising administering to the subject a therapeutically or prophylactically effective amount of an alpha-MSH analogue.
A pharmaceutical composition for treating or preventing vitiligo comprising an alpha-MSH analogue selected from compounds of the formula:
- R1—W—X—Y—Z—R2
- wherein
- R1 is absent, n-Pentadecanoyl, Ac, 4-phenylbutyrul, Ac-Gly-, Ac-Met-Glu, Ac-Nle-Glu-, or Ac-Tyr-Glu-;
- W is -His- or -D-His-;
- X is -Phe-, -D-Phe-, -Tyr-, -D-Tyr-, or -(pN02)D-Phe7-;
- Y is -Arg- or -D-Arg-;
- Z is -Trp- or -D-Trp-;
- and
- R2 is —NH2;
- -Gly-NH2;
- or -Gly-Lys-NH2,
- or a linear alpha-MSH analogue selected from the group consisting of:
- Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Lys-Gly-
- Pro-Val-NH2,
- Ac-Ser-Tyr-Ser-Nle-Asp-His-D-Phe-Arg-Trp-Lys-Gly-
- Pro-Val-NH2,
- Ac-Nle-Glu-His-D-Phe-Arg-Trp-Lys-Gly-Pro-Val-NH2,
- Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-Gly-Pro-Val-NH2,
- Ac-Nle-Asp-His-D-Phe-Arg-Trp-Gly-NH2,
- Ac-Nle-Glu-His-D-Phe-Arg-Trp-Lys-NH2,
- Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2,
- Ac-Nle-Glu-His-D-Phe-Arg-Trp-Orn-NH2,
- Ac-Nle-Asp-His-D-Phe-Arg-Trp-Orn-NH2,
- Ac-Nle-Glu-His-D-Phe-Arg-Trp-Dab-NH2,
- Ac-Nle-Asp-His-D-Phe-Arg-Trp-Dab-NH2,
- Ac-Nle-Asp-His-D-Phe-Arg-Trp-Dpr-NH2,
- Ac-Nle-Glu-His-Phe-Arg-Trp-Lys-NH2,
- and
- Ac-Nle-Asp-His-Phe-Arg-Trp-Lys-NH2,
- or a cyclic alpha-MSH analogue selected from the group consisting of:
Dependencies are inferred from the claim text.